Designed with interactome-based deep learning

Xueying Mao,Yanyi Chu,Dongqing Wei

DOI: https://doi.org/10.1038/s41589-024-01754-7

IF: 14.8

2024-10-19

Nature Chemical Biology

Abstract:Predicting prospective drug-like molecules quickly and accurately is a considerable challenge for de novo drug design. An interactome-based deep learning method has been developed that outperforms standard chemical language models.

biochemistry & molecular biology

What problem does this paper attempt to address?

A deep-learning view of chemical space designed to facilitate drug discovery

Paul Maragakis,Hunter Nisonoff,Brian Cole,David E. Shaw

DOI: https://doi.org/10.48550/arXiv.2002.02948

2020-02-08

Abstract:Drug discovery projects entail cycles of design, synthesis, and testing that yield a series of chemically related small molecules whose properties, such as binding affinity to a given target protein, are progressively tailored to a particular drug discovery goal. The use of deep learning technologies could augment the typical practice of using human intuition in the design cycle, and thereby expedite drug discovery projects. Here we present DESMILES, a deep neural network model that advances the state of the art in machine learning approaches to molecular design. We applied DESMILES to a previously published benchmark that assesses the ability of a method to modify input molecules to inhibit the dopamine receptor D2, and DESMILES yielded a 77% lower failure rate compared to state-of-the-art models. To explain the ability of DESMILES to hone molecular properties, we visualize a layer of the DESMILES network, and further demonstrate this ability by using DESMILES to tailor the same molecules used in the D2 benchmark test to dock more potently against seven different receptors.

Machine Learning
DeepDrug: A General Graph-Based Deep Learning Framework for Drug-Drug Interactions and Drug-Target Interactions Prediction

Qijin Yin,Rui Fan,Xusheng Cao,Qiao Liu,Rui Jiang,Wanwen Zeng

DOI: https://doi.org/10.15302/j-qb-022-0320

2023-01-01

Quantitative Biology

Abstract:Background: Computational approaches for accurate prediction of drug interactions, such as drug-drug interactions (DDIs) and drug-target interactions (DTIs), are highly demanded for biochemical researchers. Despite the fact that many methods have been proposed and developed to predict DDIs and DTIs respectively, their success is still limited due to a lack of systematic evaluation of the intrinsic properties embedded in the corresponding chemical structure. Methods: In this paper, we develop DeepDrug, a deep learning framework for overcoming the above limitation by using residual graph convolutional networks (Res-GCNs) and convolutional networks (CNNs) to learn the comprehensive structure- and sequence-based representations of drugs and proteins. Results: DeepDrug outperforms state-of-the-art methods in a series of systematic experiments, including binary-class DDIs, multi-class/multi-label DDIs, binary-class DTIs classification and DTIs regression tasks. Furthermore, we visualize the structural features learned by DeepDrug Res-GCN module, which displays compatible and accordant patterns in chemical properties and drug categories, providing additional evidence to support the strong predictive power of DeepDrug. Ultimately, we apply DeepDrug to perform drug repositioning on the whole DrugBank database to discover the potential drug candidates against SARS-CoV-2, where 7 out of 10 top-ranked drugs are reported to be repurposed to potentially treat coronavirus disease 2019 (COVID-19). Conclusions: To sum up, we believe that DeepDrug is an efficient tool in accurate prediction of DDIs and DTIs and provides a promising insight in understanding the underlying mechanism of these biochemical relations.
Deep-Learning-Based Drug-Target Interaction Prediction.

Ming Wen,Zhimin Zhang,Shaoyu Niu,Haozhi Sha,Ruihan Yang,Yonghuan Yun,Hongmei Lu

DOI: https://doi.org/10.1021/acs.jproteome.6b00618

2017-01-01

Journal of Proteome Research

Abstract:Identifying interactions between known drugs and targets is a major challenge in drug repositioning. In silico prediction of drug-target interaction (DTI) can speed up the expensive and time-consuming experimental work by providing the most potent DTIs. In silico prediction of DTI can also provide insights about the potential drug-drug interaction and promote the exploration of drug side effects. Traditionally, the performance of DTI prediction depends heavily on the descriptors used to represent the drugs and the target proteins. In this paper, to accurately predict new DTIs between approved drugs and targets without separating the targets into different classes, we developed a deep-learning-based algorithmic framework named DeepDTIs. It first abstracts representations from raw input descriptors using unsupervised pretraining and then applies known label pairs of interaction to build a classification model. Compared with other methods, it is found that DeepDTIs reaches or outperforms other state-of-the-art methods. The DeepDTIs can be further used to predict whether a new drug targets to some existing targets or whether a new target interacts with some existing drugs.
An Ensemble Learning-Based Method for Inferring Drug-Target Interactions Combining Protein Sequences and Drug Fingerprints

Zheng-Yang Zhao,Wen-Zhun Huang,Xin-Ke Zhan,Jie Pan,Yu-An Huang,Shan-Wen Zhang,Chang-Qing Yu

DOI: https://doi.org/10.1155/2021/9933873

2021-01-01

BioMed Research International

Abstract:Identifying the interactions of the drug-target is central to the cognate areas including drug discovery and drug reposition. Although the high-throughput biotechnologies have made tremendous progress, the indispensable clinical trials remain to be expensive, laborious, and intricate. Therefore, a convenient and reliable computer-aided method has become the focus on inferring drug-target interactions (DTIs). In this research, we propose a novel computational model integrating a pyramid histogram of oriented gradients (PHOG), Position-Specific Scoring Matrix (PSSM), and rotation forest (RF) classifier for identifying DTIs. Specifically, protein primary sequences are first converted into PSSMs to describe the potential biological evolution information. After that, PHOG is employed to mine the highly representative features of PSSM from multiple pyramid levels, and the complete describers of drug-target pairs are generated by combining the molecular substructure fingerprints and PHOG features. Finally, we feed the complete describers into the RF classifier for effective prediction. The experiments of 5-fold Cross-Validations (CV) yield mean accuracies of 88.96%, 86.37%, 82.88%, and 76.92% on four golden standard data sets (enzyme, ion channel, G protein-coupled receptors (GPCRs), and nuclear receptor, respectively). Moreover, the paper also conducts the state-of-art light gradient boosting machine (LGBM) and support vector machine (SVM) to further verify the performance of the proposed model. The experimental outcomes substantiate that the established model is feasible and reliable to predict DTIs. There is an excellent prospect that our model is capable of predicting DTIs as an efficient tool on a large scale.
An Adaptive Graph Learning Method for Automated Molecular Interactions and Properties Predictions

Yuquan Li,Chang-Yu Hsieh,Ruiqiang Lu,Xiaoqing Gong,Xiaorui Wang,Pengyong Li,Shuo Liu,Yanan Tian,Dejun Jiang,Jiaxian Yan,Qifeng Bai,Huanxiang Liu,Shengyu Zhang,Xiaojun Yao

DOI: https://doi.org/10.1038/s42256-022-00501-8

IF: 23.8

2022-01-01

Nature Machine Intelligence

Abstract:Improving drug discovery efficiency is a core and long-standing challenge in drug discovery. For this purpose, many graph learning methods have been developed to search potential drug candidates with fast speed and low cost. In fact, the pursuit of high prediction performance on a limited number of datasets has crystallized their architectures and hyperparameters, making them lose advantage in repurposing to new data generated in drug discovery. Here we propose a flexible method that can adapt to any dataset and make accurate predictions. The proposed method employs an adaptive pipeline to learn from a dataset and output a predictor. Without any manual intervention, the method achieves far better prediction performance on all tested datasets than traditional methods, which are based on hand-designed neural architectures and other fixed items. In addition, we found that the proposed method is more robust than traditional methods and can provide meaningful interpretability. Given the above, the proposed method can serve as a reliable method to predict molecular interactions and properties with high adaptability, performance, robustness and interpretability. This work takes a solid step forward to the purpose of aiding researchers to design better drugs with high efficiency. Deep learning methods can provide useful predictions for drug design, but their hyperparameters need to be carefully tweaked to give good performance on a specific problem or dataset. Li et al. present here a method that finds appropriate architectures and hyperparameters for a wide range of drug design tasks and can achieve good performance without human intervention.
Deep generative model for drug design from protein target sequence

Yangyang Chen,Zixu Wang,Lei Wang,Jianmin Wang,Pengyong Li,Dongsheng Cao,Xiangxiang Zeng,Xiucai Ye,Tetsuya Sakurai

DOI: https://doi.org/10.1186/s13321-023-00702-2

2023-01-01

Journal of Cheminformatics

Abstract:Drug discovery for a protein target is a laborious and costly process. Deep learning (DL) methods have been applied to drug discovery and successfully generated novel molecular structures, and they can substantially reduce development time and costs. However, most of them rely on prior knowledge, either by drawing on the structure and properties of known molecules to generate similar candidate molecules or extracting information on the binding sites of protein pockets to obtain molecules that can bind to them. In this paper, DeepTarget, an end-to-end DL model, was proposed to generate novel molecules solely relying on the amino acid sequence of the target protein to reduce the heavy reliance on prior knowledge. DeepTarget includes three modules: Amino Acid Sequence Embedding (AASE), Structural Feature Inference (SFI), and Molecule Generation (MG). AASE generates embeddings from the amino acid sequence of the target protein. SFI inferences the potential structural features of the synthesized molecule, and MG seeks to construct the eventual molecule. The validity of the generated molecules was demonstrated by a benchmark platform of molecular generation models. The interaction between the generated molecules and the target proteins was also verified on the basis of two metrics, drug–target affinity and molecular docking. The results of the experiments indicated the efficacy of the model for direct molecule generation solely conditioned on amino acid sequence.
Drug - Target Interaction Prediction with a Deep-Learning-based Model.

Lingwei Xie,Zhongnan Zhang,Song He,Xiaochen Bo,Xinyu Song

DOI: https://doi.org/10.1109/bibm.2017.8217693

2017-01-01

Abstract:Drug-target interaction identification is of highly importance in drug research and development. The traditional experimental paradigm is costly, while the previous in silico prediction paradigm remains a challenge because of diversified data production platforms and data scarcity. In this paper, we modeled drug-target interaction prediction as a binary classification task based on transcriptome data of drug stimulation and gene knockout from LINCS project and developed a framework with a deep-learning-based model to predict potential interactions. The evaluation results showed that not only did our framework fit data with better accuracy than other classical methods, but predicted more credible drug-target interactions. What's more, the prediction has high percentage of overlap interactions across other platforms.
Implementation of Deep Learning in Drug Design

Bo Yang,Kan Li,Xiuqin Zhong,Jun Zou

DOI: https://doi.org/10.1002/mef2.18

2022-01-01

MedComm – Future Medicine

Abstract:AbstractThe field of deep learning has witnessed dramatic and rapid progress in the past several years, largely driven by the availability of massive datasets and increased computational power. Although promising advances have been made, the implementation of deep learning in drug design is still in the vigorously developing stage. Here we summarize the frontiers and emerging applications of deep learning in drug design. We provide the background of deep learning and the architecture of several important deep neural networks for drug design and discovery, including convolutional neural networks, recurrent neural networks, transformer, deep auto‐encoder, generative adversarial networks, graph neural networks, and flow‐based neural networks. We give some examples of tasks for which these different deep neural networks are suitable. The successful employment of deep learning in drug design and discussing its further opportunities are reviewed, such as molecular representation, drug‐likeness prediction, de novo molecular generation, ligand‐protein interaction prediction, reaction, and retrosynthetic prediction. Current challenges and further possibilities are proposed to help accelerate the progress of the field, such as model interpretation, the requirement for large quantities of training datasets, hyperparameters tuning, and open source.
Deep learning integration of molecular and interactome data for protein–compound interaction prediction

Narumi Watanabe,Yuuto Ohnuki,Yasubumi Sakakibara

DOI: https://doi.org/10.1186/s13321-021-00513-3

2021-05-01

Journal of Cheminformatics

Abstract:Abstract Motivation Virtual screening, which can computationally predict the presence or absence of protein–compound interactions, has attracted attention as a large-scale, low-cost, and short-term search method for seed compounds. Existing machine learning methods for predicting protein–compound interactions are largely divided into those based on molecular structure data and those based on network data. The former utilize information on proteins and compounds, such as amino acid sequences and chemical structures; the latter rely on interaction network data, such as protein–protein interactions and compound–compound interactions. However, there have been few attempts to combine both types of data in molecular information and interaction networks. Results We developed a deep learning-based method that integrates protein features, compound features, and multiple types of interactome data to predict protein–compound interactions. We designed three benchmark datasets with different difficulties and applied them to evaluate the prediction method. The performance evaluations show that our deep learning framework for integrating molecular structure data and interactome data outperforms state-of-the-art machine learning methods for protein–compound interaction prediction tasks. The performance improvement is statistically significant according to the Wilcoxon signed-rank test. This finding reveals that the multi-interactome data captures perspectives other than amino acid sequence homology and chemical structure similarity and that both types of data synergistically improve the prediction accuracy. Furthermore, experiments on the three benchmark datasets show that our method is more robust than existing methods in accurately predicting interactions between proteins and compounds that are unseen in training samples.

chemistry, multidisciplinary,computer science, interdisciplinary applications, information systems
Prospective de novo drug design with deep interactome learning

Kenneth Atz,Leandro Cotos,Clemens Isert,Maria Håkansson,Dorota Focht,Mattis Hilleke,David F. Nippa,Michael Iff,Jann Ledergerber,Carl C. G. Schiebroek,Valentina Romeo,Jan A. Hiss,Daniel Merk,Petra Schneider,Bernd Kuhn,Uwe Grether,Gisbert Schneider

DOI: https://doi.org/10.1038/s41467-024-47613-w

IF: 16.6

2024-04-24

Nature Communications

Abstract:De novo drug design aims to generate molecules from scratch that possess specific chemical and pharmacological properties. We present a computational approach utilizing interactome-based deep learning for ligand- and structure-based generation of drug-like molecules. This method capitalizes on the unique strengths of both graph neural networks and chemical language models, offering an alternative to the need for application-specific reinforcement, transfer, or few-shot learning. It enables the "zero-shot" construction of compound libraries tailored to possess specific bioactivity, synthesizability, and structural novelty. In order to proactively evaluate the deep interactome learning framework for protein structure-based drug design, potential new ligands targeting the binding site of the human peroxisome proliferator-activated receptor (PPAR) subtype gamma are generated. The top-ranking designs are chemically synthesized and computationally, biophysically, and biochemically characterized. Potent PPAR partial agonists are identified, demonstrating favorable activity and the desired selectivity profiles for both nuclear receptors and off-target interactions. Crystal structure determination of the ligand-receptor complex confirms the anticipated binding mode. This successful outcome positively advocates interactome-based de novo design for application in bioorganic and medicinal chemistry, enabling the creation of innovative bioactive molecules.

multidisciplinary sciences
MolDesigner: Interactive Design of Efficacious Drugs with Deep Learning

Kexin Huang,Tianfan Fu,Dawood Khan,Ali Abid,Ali Abdalla,Abubakar Abid,Lucas M. Glass,Marinka Zitnik,Cao Xiao,Jimeng Sun

DOI: https://doi.org/10.48550/arXiv.2010.03951

2020-10-05

Quantitative Methods

Abstract:The efficacy of a drug depends on its binding affinity to the therapeutic target and pharmacokinetics. Deep learning (DL) has demonstrated remarkable progress in predicting drug efficacy. We develop MolDesigner, a human-in-the-loop web user-interface (UI), to assist drug developers leverage DL predictions to design more effective drugs. A developer can draw a drug molecule in the interface. In the backend, more than 17 state-of-the-art DL models generate predictions on important indices that are crucial for a drug's efficacy. Based on these predictions, drug developers can edit the drug molecule and reiterate until satisfaction. MolDesigner can make predictions in real-time with a latency of less than a second.
Deep Learning-Based Modeling of Drug–Target Interaction Prediction Incorporating Binding Site Information of Proteins

D'Souza, Sofia,Prema, K. V.,Balaji, S.,Shah, Ronak

DOI: https://doi.org/10.1007/s12539-023-00557-z

2023-03-27

Abstract:Chemogenomics, also known as proteochemometrics, covers various computational methods for predicting interactions between related drugs and targets on large-scale data. Chemogenomics is used in the early stages of drug discovery to predict the off-target effects of proteins against therapeutic candidates. This study aims to predict unknown ligand–target interactions using one-dimensional SMILES as inputs for ligands and binding site residues for proteins in a computationally efficient manner. We first formulate a Deep learning CNN model using one-dimensional SMILES for drugs and motif-rich binding pocket subsequences of proteins as inputs. We evaluate and compare the proposed deep learning model trained on expert-based features against shallow feature-based machine learning methods. The proposed method achieved better or similar performance on the MSE and AUPR metrics than the shallow methods. Additionally, We show that our deep learning model, DeepPS is computationally more efficient than the deep learning model trained on full-length raw sequences of proteins. We conclude that a beneficial research approach would be to integrate structural information of proteins for modeling drug-target interaction prediction of large datasets for more interpretability, high throughput, and broad applicability.

mathematical & computational biology
A deep learning-based method for drug-target interaction prediction based on long short-term memory neural network

Yan-Bin Wang,Zhu-Hong You,Shan Yang,Hai-Cheng Yi,Zhan-Heng Chen,Kai Zheng

DOI: https://doi.org/10.1186/s12911-020-1052-0

IF: 3.298

2020-03-01

BMC Medical Informatics and Decision Making

Abstract:Abstract Background The key to modern drug discovery is to find, identify and prepare drug molecular targets. However, due to the influence of throughput, precision and cost, traditional experimental methods are difficult to be widely used to infer these potential Drug-Target Interactions (DTIs). Therefore, it is urgent to develop effective computational methods to validate the interaction between drugs and target. Methods We developed a deep learning-based model for DTIs prediction. The proteins evolutionary features are extracted via Position Specific Scoring Matrix (PSSM) and Legendre Moment (LM) and associated with drugs molecular substructure fingerprints to form feature vectors of drug-target pairs. Then we utilized the Sparse Principal Component Analysis (SPCA) to compress the features of drugs and proteins into a uniform vector space. Lastly, the deep long short-term memory (DeepLSTM) was constructed for carrying out prediction. Results A significant improvement in DTIs prediction performance can be observed on experimental results, with AUC of 0.9951, 0.9705, 0.9951, 0.9206, respectively, on four classes important drug-target datasets. Further experiments preliminary proves that the proposed characterization scheme has great advantage on feature expression and recognition. We also have shown that the proposed method can work well with small dataset. Conclusion The results demonstration that the proposed approach has a great advantage over state-of-the-art drug-target predictor. To the best of our knowledge, this study first tests the potential of deep learning method with memory and Turing completeness in DTIs prediction.

medical informatics
Generating and screening de novo compounds against given targets using ultrafast deep learning models as core components

Haiping Zhang,Konda Mani Saravanan,Yang Yang,Yanjie Wei,Pan Yi,John Z H Zhang

DOI: https://doi.org/10.1093/bib/bbac226

2022-07-18

Abstract:Deep learning is an artificial intelligence technique in which models express geometric transformations over multiple levels. This method has shown great promise in various fields, including drug development. The availability of public structure databases prompted the researchers to use generative artificial intelligence models to narrow down their search of the chemical space, a novel approach to chemogenomics and de novo drug development. In this study, we developed a strategy that combined an accelerated LSTM_Chem (long short-term memory for de novo compounds generation), dense fully convolutional neural network (DFCNN), and docking to generate a large number of de novo small molecular chemical compounds for given targets. To demonstrate its efficacy and applicability, six important targets that account for various human disorders were used as test examples. Moreover, using the M protease as a proof-of-concept example, we find that iteratively training with previously selected candidates can significantly increase the chance of obtaining novel compounds with higher and higher predicted binding affinities. In addition, we also check the potential benefit of obtaining reliable final de novo compounds with the help of MD simulation and metadynamics simulation. The generation of de novo compounds and the discovery of binders against various targets proposed here would be a practical and effective approach. Assessing the efficacy of these top de novo compounds with biochemical studies is promising to promote related drug development.
Deep Kernel Inversion: Rapid and Accurate Molecular Interaction Prediction for Drug Design

Seth A. Myers,Chad Miller,Kyler Lugo,Thi Trinh,Chang-wook Lee,Naveen Arunachalam,Hannah Chen,Denis Drygin,James Martineau

DOI: https://doi.org/10.1101/2024.11.19.624391

2024-11-21

Abstract:Computational drug design offers the opportunity to dramatically accelerate novel therapeutics for untreated diseases. Designing compounds with optimal efficacy and specificity, however, requires understanding and optimizing immense numbers of molecular interactions. While advances in predicting one-to-one molecular interactions continue, there has been limited progress in scaling one-to-many or many-to-many molecular interaction models. In this paper, we introduce a deep learning framework that embeds molecules into a high-dimensional vector space, which we have named Deep Kernel Inversion. In this framework, the dot product between vectors accurately predicts molecular interactions. This approach reduces the complexity of predicting an entire molecular interaction network from O(n2) to O(n), enabling new molecular design tasks previously inaccessible to computational approaches. In the case of human protein-protein interactions (PPI), we demonstrate a 100,000 fold decrease in the computation required to map the full human PPI network. We also demonstrate best-in-class performance across multiple molecular interaction tasks with this approach. This work offers a new way forward in scaling accurate molecular interaction predictions with applications in mapping biological pathways, target discovery, drug design, and therapeutic development.

Biology
DeepLPI: a novel deep learning-based model for protein–ligand interaction prediction for drug repurposing

Bomin Wei,Yue Zhang,Xiang Gong

DOI: https://doi.org/10.1038/s41598-022-23014-1

IF: 4.6

2022-10-29

Scientific Reports

Abstract:The substantial cost of new drug research and development has consistently posed a huge burden for both pharmaceutical companies and patients. In order to lower the expenditure and development failure rate, repurposing existing and approved drugs by identifying interactions between drug molecules and target proteins based on computational methods have gained growing attention. Here, we propose the DeepLPI, a novel deep learning-based model that mainly consists of ResNet-based 1-dimensional convolutional neural network (1D CNN) and bi-directional long short term memory network (biLSTM), to establish an end-to-end framework for protein–ligand interaction prediction. We first encode the raw drug molecular sequences and target protein sequences into dense vector representations, which go through two ResNet-based 1D CNN modules to derive features, respectively. The extracted feature vectors are concatenated and further fed into the biLSTM network, followed by the MLP module to finally predict protein–ligand interaction. We downloaded the well-known BindingDB and Davis dataset for training and testing our DeepLPI model. We also applied DeepLPI on a COVID-19 dataset for externally evaluating the prediction ability of DeepLPI. To benchmark our model, we compared our DeepLPI with the baseline methods of DeepCDA and DeepDTA, and observed that our DeepLPI outperformed these methods, suggesting the high accuracy of the DeepLPI towards protein–ligand interaction prediction. The high prediction performance of DeepLPI on the different datasets displayed its high capability of protein–ligand interaction in generalization, demonstrating that the DeepLPI has the potential to pinpoint new drug-target interactions and to find better destinations for proven drugs.

multidisciplinary sciences
Application advances of deep learning methods for de novo drug design and molecular dynamics simulation

Qifeng Bai,Shuo Liu,Yanan Tian,Tingyang Xu,Antonio Jesús Banegas‐Luna,Horacio Pérez‐Sánchez,Junzhou Huang,Huanxiang Liu,Xiaojun Yao

DOI: https://doi.org/10.1002/wcms.1581

2021-10-14

WIREs Computational Molecular Science

Abstract:De novo drug design is a stationary way to build novel ligands in the confined pocket of receptor by assembling the atoms or fragments, while molecular dynamics (MD) simulation is a dynamical way to study the interaction mechanism between the ligands and receptors based on the molecular force field. De novo drug design and MD simulation are effective tools for novel drug discovery. With the development of technology, deep learning methods, and interpretable machine learning (IML) have emerged in the research area of drug design. Deep learning methods and IML can be used further to improve the efficiency and accuracy of de novo drug design and MD simulations. The application summary of deep learning methods for de novo drug design, MD simulations, and IML can further promote the technical development of drug discovery. In this article, two major workflow methods and the related components of classical algorithm and deep learning are described for de novo drug design from a new perspective. The application progress of deep learning is also summarized for MD simulations. Furthermore, IML is introduced for the deep learning model interpretability of de novo drug design and MD simulations. Our paper deals with an interesting topic about deep learning applications of de novo drug design and MD simulations for the scientific community.This article is categorized under: Data Science > ChemoinformaticsData Science > Artificial Intelligence/Machine Learning
519. DeepLPI: A Novel Drug Repurposing Model based on Ligand-Protein Interaction Using Deep Learning

Bomin Wei,Yue Zhang,Xiang Gong

DOI: https://doi.org/10.1093/ofid/ofac492.574

2022-12-01

Open Forum Infectious Diseases

Abstract:Abstract Background Drug repurposing has gained increased attention because it proposes to find effective cures for new diseases from approved drugs to lower development costs and time, and computational prediction of protein-ligand interactions (PLI) can provide accurate and fast drug screening. The shortcomings of existing machine learning-based methods for PLI prediction include 1) using human-selected features leads to loss of information and therefore lower accuracy and 2) using limited 3D structure data for input leads to lower generalizability. Methods To address the shortcomings, I proposed DeepLPI, a novel deep learning-based model that takes as input the raw sequences of drug molecules and proteins. DeepLPI applied pre-trained embedding models to encode the raw sequences into dense vector representations, which were then fed into 1D-CNN and biLSTM to obtain predictions. BindingDB dataset was used for model training and performance evaluation that is compared with a start-of-the-art method DeepCDA. Fig 1.Principle of NLP-inspired deep learning-based methods to embed drug SMILES strings (Mol2vec) and protein sequences (ProSE). Similar drugs or proteins will be in close distance after the embedding because these methods can capture contextual information.Fig 2.Model architecture from input to output of DeepLPI. Results Results showed that the DeepLPI reached an overall AUROC of 0.79 based on the BindingDB internal test, 76% better than DeepCDA. DeepLPI also outperformed DeepCDA using the external Davis dataset (AUROC=0.53) and COVID-19 3CL Protease dataset (AUROC=0.61). Figure 3.A randomly reserved part of the BindingDB dataset was grouped into four cases for testing, according to whether the drug molecules or the proteins are seen in the training set. (Note that the drug-target pairs in the test set are excluded from the training set.)Fig 4.We compare with DeepCDA, a recently published DTI prediction model that reported to be better than previous models. DeepLPI is 76% better in accuracy metric AUROC in classification tasks.Fig 5.As a preliminary attempt, the model trained on BindingDB was applied to a recent COVID-19 dataset targeting the 3CL-protease, which reported 897 small molecule drugs. Our model is better than the baseline method by 25%. Conclusion The high performance of DeepLPI suggests that our model has the potential to identify new COVID-19 drugs when applied to approved drugs. The generalizability of the model also promises applications to diseases in a wider scope. Disclosures All Authors: No reported disclosures.

immunology,infectious diseases,microbiology
A deep learning method for drug-target affinity prediction based on sequence interaction information mining

Mingjian Jiang,Yunchang Shao,Yuanyuan Zhang,Wei Zhou,Shunpeng Pang

DOI: https://doi.org/10.7717/peerj.16625

IF: 3.061

2023-12-11

PeerJ

Abstract:Background: A critical aspect of in silico drug discovery involves the prediction of drug-target affinity (DTA). Conducting wet lab experiments to determine affinity is both expensive and time-consuming, making it necessary to find alternative approaches. In recent years, deep learning has emerged as a promising technique for DTA prediction, leveraging the substantial computational power of modern computers. Methods: We proposed a novel sequence-based approach, named KC-DTA, for predicting drug-target affinity (DTA). In this approach, we converted the target sequence into two distinct matrices, while representing the molecule compound as a graph. The proposed method utilized k-mers analysis and Cartesian product calculation to capture the interactions and evolutionary information among various residues, enabling the creation of the two matrices for target sequence. For molecule, it was represented by constructing a molecular graph where atoms serve as nodes and chemical bonds serve as edges. Subsequently, the obtained target matrices and molecule graph were utilized as inputs for convolutional neural networks (CNNs) and graph neural networks (GNNs) to extract hidden features, which were further used for the prediction of binding affinity. Results: In order to evaluate the effectiveness of the proposed method, we conducted several experiments and made a comprehensive comparison with the state-of-the-art approaches using multiple evaluation metrics. The results of our experiments demonstrated that the KC-DTA method achieves high performance in predicting drug-target affinity (DTA). The findings of this research underscore the significance of the KC-DTA method as a valuable tool in the field of in silico drug discovery, offering promising opportunities for accelerating the drug development process. All the data and code are available for access on https://github.com/syc2017/KCDTA.
Structure-based <i>de novo</i> drug design using 3D deep generative models

Yibo Li,Jianfeng Pei,Luhua Lai

DOI: https://doi.org/10.1039/d1sc04444c

IF: 8.4

2021-01-01

Chemical Science

Abstract:Deep generative models are attracting much attention in the field of de novo molecule design. Compared to traditional methods, deep generative models can be trained in a fully data-driven way with little requirement for expert knowledge. Although many models have been developed to generate 1D and 2D molecular structures, 3D molecule generation is less explored, and the direct design of drug-like molecules inside target binding sites remains challenging. In this work, we introduce DeepLigBuilder, a novel deep learning-based method for de novo drug design that generates 3D molecular structures in the binding sites of target proteins. We first developed Ligand Neural Network (L-Net), a novel graph generative model for the end-to-end design of chemically and conformationally valid 3D molecules with high drug-likeness. Then, we combined L-Net with Monte Carlo tree search to perform structure-based de novo drug design tasks. In the case study of inhibitor design for the main protease of SARS-CoV-2, DeepLigBuilder suggested a list of drug-like compounds with novel chemical structures, high predicted affinity, and similar binding features to those of known inhibitors. The current version of L-Net was trained on drug-like compounds from ChEMBL, which could be easily extended to other molecular datasets with desired properties based on users' demands and applied in functional molecule generation. Merging deep generative models with atomic-level interaction evaluation, DeepLigBuilder provides a state-of-the-art model for structure-based de novo drug design and lead optimization.

Designed with interactome-based deep learning

A deep-learning view of chemical space designed to facilitate drug discovery

DeepDrug: A General Graph-Based Deep Learning Framework for Drug-Drug Interactions and Drug-Target Interactions Prediction

Deep-Learning-Based Drug-Target Interaction Prediction.

An Ensemble Learning-Based Method for Inferring Drug-Target Interactions Combining Protein Sequences and Drug Fingerprints

An Adaptive Graph Learning Method for Automated Molecular Interactions and Properties Predictions

Deep generative model for drug design from protein target sequence

Drug - Target Interaction Prediction with a Deep-Learning-based Model.

Implementation of Deep Learning in Drug Design

Deep learning integration of molecular and interactome data for protein–compound interaction prediction

Prospective de novo drug design with deep interactome learning

MolDesigner: Interactive Design of Efficacious Drugs with Deep Learning

Deep Learning-Based Modeling of Drug–Target Interaction Prediction Incorporating Binding Site Information of Proteins

A deep learning-based method for drug-target interaction prediction based on long short-term memory neural network

Generating and screening de novo compounds against given targets using ultrafast deep learning models as core components

Deep Kernel Inversion: Rapid and Accurate Molecular Interaction Prediction for Drug Design

DeepLPI: a novel deep learning-based model for protein–ligand interaction prediction for drug repurposing

Application advances of deep learning methods for de novo drug design and molecular dynamics simulation

519. DeepLPI: A Novel Drug Repurposing Model based on Ligand-Protein Interaction Using Deep Learning

A deep learning method for drug-target affinity prediction based on sequence interaction information mining

Structure-based <i>de novo</i> drug design using 3D deep generative models